767.76
price up icon1.35%   10.22
after-market After Hours: 767.76
loading
Lilly Eli Co stock is traded at $767.76, with a volume of 8.93M. It is up +1.35% in the last 24 hours and up +1.90% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$757.54
Open:
$811.35
24h Volume:
8.93M
Relative Volume:
2.49
Market Cap:
$690.46B
Revenue:
$40.86B
Net Income/Loss:
$8.37B
P/E Ratio:
141.67
EPS:
5.4193
Net Cash Flow:
$-2.28B
1W Performance:
-2.71%
1M Performance:
+1.90%
6M Performance:
-13.34%
1Y Performance:
+34.65%
1-Day Range:
Value
$766.61
$811.35
1-Week Range:
Value
$752.39
$811.35
52-Week Range:
Value
$567.02
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
43,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
767.76 690.46B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
85.00 377.54B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
144.47 347.83B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
175.58 310.27B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
98.05 248.03B 63.17B 12.15B 14.84B 4.77

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
10:03 AM

Novo Nordisk raises Eli Lilly post CagriSema data (NVO:NYSE) - Seeking Alpha

10:03 AM
pulisher
08:43 AM

2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves - The Motley Fool

08:43 AM
pulisher
07:30 AM

Novo obesity data positive for Eli Lilly and Amgen, says UBS - Yahoo Finance

07:30 AM
pulisher
07:00 AM

FDA says knockoff versions of Lilly obesity drug must come off the market - Wyoming Tribune

07:00 AM
pulisher
05:40 AM

Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - AOL

05:40 AM
pulisher
Dec 20, 2024

FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea - ABC News

Dec 20, 2024
pulisher
Dec 20, 2024

The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly given green light in US to treat sleep disorder with weight-loss drug - Financial Times

Dec 20, 2024
pulisher
Dec 20, 2024

Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea - Reuters

Dec 20, 2024
pulisher
Dec 20, 2024

Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea By Reuters - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S. - STAT

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly's Zepbound gains sleep apnea indication (LLY:NYSE) - Seeking Alpha

Dec 20, 2024
pulisher
Dec 20, 2024

Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea - The Denver Gazette

Dec 20, 2024
pulisher
Dec 20, 2024

Lilly’s Zepbound Grabs First Drug Approval for Sleep Apnea in US - Bloomberg

Dec 20, 2024
pulisher
Dec 20, 2024

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC

Dec 20, 2024
pulisher
Dec 20, 2024

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Investors | Eli Lilly and Company

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly and Company (NYSE:LLY) Trading 4.2% HigherHere's Why - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Nvidia, Eli Lilly lead Friday's market cap stock movers By Investing.com - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

Nvidia, Eli Lilly lead Friday's market cap stock movers - Investing.com India

Dec 20, 2024
pulisher
Dec 20, 2024

Lilly Cements Weight Loss Lead After Novo Trial Setback - Bloomberg

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now - Seeking Alpha

Dec 20, 2024
pulisher
Dec 20, 2024

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up - The Motley Fool

Dec 20, 2024
pulisher
Dec 20, 2024

Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it - CNN

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly and Company (NYSE:LLY) Shares Gap UpHere's What Happened - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly, Avago lead market cap stock movers this Friday - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

In weight loss battle, Novo and Lilly face growing offensive from licensed copies - Reuters

Dec 20, 2024
pulisher
Dec 20, 2024

LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List - Yahoo Finance

Dec 20, 2024
pulisher
Dec 20, 2024

Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla - The Wall Street Journal

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly shares reiterate buy rating on Phase 3 study results - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Citi Reiterates Buy Rating on Eli Lilly (LLY) - StreetInsider.com

Dec 20, 2024
pulisher
Dec 20, 2024

FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation - Yahoo Finance

Dec 20, 2024
pulisher
Dec 20, 2024

Eli Lilly (LLY) stock: Why It’s a strong buy amid breakthrough developments - The Africa Logistics

Dec 20, 2024
pulisher
Dec 20, 2024

Bernstein optimistic on Eli Lilly shares despite limited near-term impact from Tirzepatide - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Novo Nordisk sinks on latest data, Lilly gains - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next - Yahoo Finance

Dec 20, 2024
pulisher
Dec 19, 2024

US FDA says Lilly's weight-loss drug shortage is resolved - Reuters.com

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’ - Insider Monkey

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls - Yahoo Finance

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lilly and Company (NYSE:LLY) Shares Down 1.2%Should You Sell? - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

US FDA says Lilly’s weight-loss drug shortage is resolved - CNN

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA - TipRanks

Dec 19, 2024
pulisher
Dec 19, 2024

Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies - Bloomberg

Dec 19, 2024
pulisher
Dec 19, 2024

FDA Says Shortage of Eli Lilly’s Zepbound is Over, But Gives Compounders a Grace Period - Yahoo! Voices

Dec 19, 2024
pulisher
Dec 19, 2024

Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copycats - The Business of Fashion

Dec 19, 2024
pulisher
Dec 19, 2024

Lilly’s US weight-loss drug shortage ends, curtailing copycats - Detroit News

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lilly’s Zepbound Shortage Is Officially Over, FDA Says - Yahoo! Voices

Dec 19, 2024
pulisher
Dec 19, 2024

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.

Dec 19, 2024
pulisher
Dec 19, 2024

Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook - Seeking Alpha

Dec 19, 2024

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general NVO
$85.00
price down icon 17.83%
drug_manufacturers_general JNJ
$144.47
price up icon 0.62%
$175.58
price up icon 2.37%
drug_manufacturers_general MRK
$98.05
price down icon 1.48%
drug_manufacturers_general NVS
$97.11
price up icon 0.35%
Cap:     |  Volume (24h):